New drug combo shows promise for Hard-to-Treat blood cancer

NCT ID NCT02537613

Ongoing Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 1 study tests a combination of two drugs, ibrutinib and obinutuzumab, in 54 people with chronic lymphocytic leukemia (CLL) that has returned or not responded to prior treatment. The main goal is to check safety and find the best dosing schedule. Researchers will also look at how well the combination shrinks or controls the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ibrutinib and obinutuzumab
What this could lead to: If it works, this could offer a new treatment option for people with CLL that has come back or not responded to other therapies.
What could go wrong: This is a small, early-phase trial focused on safety, not proof of effectiveness. The combination may cause side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
University of Rochester Wilmot Cancer Inst.

Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.